373Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years
versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS,
a randomised trial. Lancet. 2013;381:805–16.
de la Iglesia N, Konopka G, Puram SV, et al. Identifi cation of a PTEN-regulated STAT3 brain
tumor suppressor pathway. Genes Dev. 2008;22:449–62.
Deeken JF, Cormier T, Price DK, et al. A pharmacogenetic study of docetaxel and thalidomide in
patients with castration-resistant prostate cancer using the DMET genotyping platform.
Pharmacogenomics J. 2010;10:191–9.
Dehm SM. mRNA splicing variants: exploiting modularity to outwit cancer therapy. Cancer Res.
2013;73:5309–14.
Diaz Jr LA, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted
EGFR blockade in colorectal cancers. Nature. 2012;486:537–40.
Diehn M, Nardini C, Wang DS, et al. Identifi cation of noninvasive imaging surrogates for brain
tumor gene-expression modules. Proc Natl Acad Sci U S A. 2008;105:5213–8.
Ding Z, Wei Y. Therapeutic vaccine for melanoma: the untouched grail? Expert Rev Vaccines.
2007;6:907–11.
Doebele RC, Vaishnavi A, Capelletti M, et al. NTRK1 gene fusions as a novel oncogene target in
lung cancer. J Clin Oncol 2013;31 suppl: abstr #8023.
Donovan MJ, Hamann S, Clayton M, et al. Systems pathology approach for the prediction of pros-
tate cancer progression after radical prostatectomy. J Clin Oncol. 2008;26:3923–9.
Douillard JY, Oliner KS, Siena S, et al. Panitumumab–FOLFOX4 treatment and RAS mutations in
colorectal cancer. N Engl J Med. 2013;369:1023–34.
Drier Y, Sheffer M, Domany E. Pathway-based personalized analysis of cancer. Proc Natl Acad Sci
U S A. 2013;110:6388–93.
Du W, Elemento O. Cancer systems biology: embracing complexity to develop better anticancer
therapeutic strategies. Oncogene 15 Sept 2014. doi: 10.1038/onc.2014.291.
Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-
myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory
metastatic melanoma. J Clin Oncol. 2005;23:2346–57.
Edlund K, Larsson O, Ameur A, et al. Data-driven unbiased curation of the TP53 tumor suppressor
gene mutation database and validation by ultradeep sequencing of human tumors. Proc Natl
Acad Sci U S A. 2012;109:9551–6.
Ellis MJ, Tao Y, Luo J, et al. Outcome prediction for estrogen receptor-positive breast cancer based
on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst. 2008;100:
1380–8.
Emerling BM, Benes CH, Poulogiannis G, et al. Identifi cation of CDCP1 as a hypoxia-inducible
factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma
patients. Proc Natl Acad Sci U S A. 2013;110:3483–8.
Eschrich SA, Pramana J, Zhang H, et al. A gene expression model of intrinsic tumor radiosensitiv-
ity: prediction of response and prognosis after chemoradiation. Int J Radiat Oncol Biol Phys.
2009;75:489–96.
Eschrich SA, Fulp WJ, Pawitan Y, et al. Validation of a radiosensitivity molecular signature in
breast cancer. Clin Cancer Res. 2012;18:5134–43.
Faratian D, Goltsov A, Lebedeva G, et al. Systems biology reveals new strategies for personalizing
cancer medicine and confi rms the role of PTEN in resistance to trastuzumab. Cancer Res.
2009;69:6713–20.
Fenton TR, Nathanson D, Ponte de Albuquerque C, et al. Resistance to EGF receptor inhibitors in
glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proc
Natl Acad Sci U S A. 2012;109:14164–9.
Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic mela-
noma. N Engl J Med. 2010;363:809–19.
Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated
melanoma. N Engl J Med. 2012;367:107–14.
References